Biotech news for Saturday, May 16, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Earnings Call Insights: Sangamo Therapeutics (SGMO) Q1 2026 Management View "In the short time since our fourth quarter earnings call, we have continued to advance the rolling submission of the BLA for ST-920 in Fabry disease and made progress across our
Zymeworks ( ZYME ) on Thursday said its board approved a new 2026 share repurchase program authorizing the company to buy back up to $125M of its common stock. The biotechnology company also terminated its prior 2025 repurchase plan, under which it repurchased
Earnings Call Insights: Pelthos Therapeutics (PTHS) Q1 2026 Management View "The first quarter of 2026 was a successful one for Pelthos, with strong execution and progress made in several key areas" (CEO, President & Director Scott Plesha). "We experienced…